blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2832746

EP2832746 - Anti-Ang2 antibody [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.05.2019
Database last updated on 30.10.2024
FormerThe patent has been granted
Status updated on  15.06.2018
FormerGrant of patent is intended
Status updated on  14.02.2018
FormerExamination is in progress
Status updated on  16.01.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Samsung Electronics Co., Ltd.
129, Samsung-ro
Yeongtong-gu
Suwon-si
Gyeonggi-do 443-742 / KR
[2018/29]
Former [2015/06]For all designated states
Samsung Electronics Co., Ltd
129, Samsung-ro
Yeongtong-gu
Suwon-si
Gyeonggi-do 443-742 / KR
Inventor(s)01 / Kim, Kyung Eun
c/o Bio Lab
Samsung Advanced Inst. of Technology
Nongseo-ro
Giheung-gu
Yongin-si Gyeonggi-do / KR
02 / Oh, Seung Ja
5-406, Hanyang APT.
Sanggye-dong
Nowon-gu
Seoul / KR
03 / Lee, Hyo Seon
620-2808, 41, Dongtanbanseok-ro
Hwaseong-si Gyeonggi-do / KR
04 / Han, Sang Yeul
108-203, Tabsil-ro 15
Giheung-gu
Yongin-si Gyeonggi-do / KR
 [2015/06]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2018/29]
Former [2015/06]Grünecker, Kinkeldey, Stockmair & Schwanhäusser
Anwaltssozietät
Leopoldstrasse 4
80802 München / DE
Application number, filing date14178844.829.07.2014
[2015/06]
Priority number, dateKR2013008928129.07.2013         Original published format: KR 20130089281
KR2013010674905.09.2013         Original published format: KR 20130106749
[2015/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2832746
Date:04.02.2015
Language:EN
[2015/06]
Type: B1 Patent specification 
No.:EP2832746
Date:18.07.2018
Language:EN
[2018/29]
Search report(s)(Supplementary) European search report - dispatched on:EP08.12.2014
ClassificationIPC:C07K16/22, A61P35/00, A61P9/14, A61P37/06, A61K39/395
[2018/07]
CPC:
C07K16/22 (EP,US); A61K38/1891 (EP,US); A61K39/395 (EP,US);
A61K39/3955 (US); A61P35/00 (EP); A61P37/06 (EP);
A61P9/14 (EP); G01N33/74 (US); A61K2039/505 (EP,US);
C07K2317/34 (EP,US); C07K2317/55 (EP,US); C07K2317/565 (US);
C07K2317/74 (EP,US); C07K2317/75 (EP,US); C07K2317/76 (EP,US);
C07K2317/77 (EP,US); C07K2317/92 (EP,US); G01N2333/515 (US);
G01N2333/71 (US); G01N2500/02 (US) (-)
Former IPC [2015/06]C07K16/22, A61P35/00, A61P9/14, A61P37/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/38]
Former [2015/06]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Anti-ANG2-Antikörper[2015/06]
English:Anti-Ang2 antibody[2015/06]
French:Anticorps anti-ANG2[2015/06]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure04.08.2015Amendment by applicant (claims and/or description)
04.08.2015Examination requested  [2015/38]
15.03.2016Despatch of a communication from the examining division (Time limit: M04)
25.07.2016Reply to a communication from the examining division
05.09.2016Despatch of a communication from the examining division (Time limit: M04)
13.01.2017Reply to a communication from the examining division
08.02.2017Despatch of a communication from the examining division (Time limit: M04)
02.06.2017Reply to a communication from the examining division
16.08.2017Despatch of a communication from the examining division (Time limit: M04)
19.12.2017Reply to a communication from the examining division
15.02.2018Communication of intention to grant the patent
05.06.2018Fee for grant paid
05.06.2018Fee for publishing/printing paid
05.06.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18172370.1  / EP3381940
Opposition(s)23.04.2019No opposition filed within time limit [2019/26]
Fees paidRenewal fee
27.07.2016Renewal fee patent year 03
28.07.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.07.2014
AL18.07.2018
AT18.07.2018
CY18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
MK18.07.2018
NL18.07.2018
PL18.07.2018
PT18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
TR18.07.2018
IE29.07.2018
LU29.07.2018
MT29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
[2020/31]
Former [2020/28]HU29.07.2014
AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
PT18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
TR18.07.2018
IE29.07.2018
LU29.07.2018
MT29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2020/16]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
TR18.07.2018
IE29.07.2018
LU29.07.2018
MT29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2020/08]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
IE29.07.2018
LU29.07.2018
MT29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/37]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SI18.07.2018
SK18.07.2018
SM18.07.2018
IE29.07.2018
LU29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/33]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
SM18.07.2018
IE29.07.2018
LU29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/26]AL18.07.2018
AT18.07.2018
CZ18.07.2018
DK18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
SM18.07.2018
LU29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/23]AL18.07.2018
AT18.07.2018
CZ18.07.2018
EE18.07.2018
ES18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
MC18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
SK18.07.2018
LU29.07.2018
BE31.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/22]AL18.07.2018
AT18.07.2018
CZ18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
NL18.07.2018
PL18.07.2018
RO18.07.2018
RS18.07.2018
SE18.07.2018
LU29.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/21]AL18.07.2018
AT18.07.2018
FI18.07.2018
HR18.07.2018
IT18.07.2018
LT18.07.2018
LV18.07.2018
NL18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
LU29.07.2018
CH31.07.2018
LI31.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/17]AL18.07.2018
AT18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
NL18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
LU29.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/12]AL18.07.2018
AT18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
LV18.07.2018
NL18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/11]AT18.07.2018
FI18.07.2018
HR18.07.2018
LT18.07.2018
NL18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/10]AT18.07.2018
FI18.07.2018
LT18.07.2018
NL18.07.2018
PL18.07.2018
RS18.07.2018
SE18.07.2018
BG18.10.2018
NO18.10.2018
GR19.10.2018
IS18.11.2018
Former [2019/08]FI18.07.2018
LT18.07.2018
NL18.07.2018
NO18.10.2018
IS18.11.2018
Former [2019/07]LT18.07.2018
NL18.07.2018
Former [2019/04]NL18.07.2018
Documents cited:Search[XYI]WO2006045049  (AMGEN INC [US], et al) [X] 1,2,7,11,14 * page 104 * * examples 4-5 * [Y] 8 [I] 3,9,12,13;
 [XI]WO2006068953  (ABGENIX INC [US], et al) [X] 1,5,10,11,14 * example 15 * * paragraph [0199] * [I] 3;
 [X]WO2006118350  (MOCHIDA PHARM CO LTD [JP], et al) [X] 15* sequence 231 *;
 [T]  - BARTON WILLIAM A ET AL, "Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex", NATURE STRUCTURAL & MOLECULAR BIOLOGY, NATURE PUBLISHING GROUP, US, (20060601), vol. 13, no. 6, doi:10.1097/ACO.0B013E328332A473, ISSN 1545-9985, pages 524 - 532, XP009140199 [T] * page 524, column right * * figure 1B *

DOI:   http://dx.doi.org/10.1097/ACO.0b013e328332a473
 [A]  - Santa Cruz Biotechnology, inc., "Ang-2 (F-1): sc-74403", (20130322), Santa Cruz Biotechnology Online Catalogue, URL: http://datasheets.scbt.com/sc-74403.pdf, (20141113), XP002732470 [A] 1-15 * the whole document *
 [AP]  - abcam, "Anti-Angiopoietin 2 antibody ab8452", (20141113), abcam Online Catalogue, URL: http://www.abcam.com/Angiopoietin-2-antibody-ab8452.pdf, (20141113), XP002732471 [AP] 1-15 * the whole document *
 [XY]  - SRIRAJASKANTHAN R ET AL, "Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis.", ENDOCRINE-RELATED CANCER SEP 2009, (200909), vol. 16, no. 3, ISSN 1479-6821, pages 967 - 976, XP002732472 [X] 1,14 * page 969, column right * [Y] 10

DOI:   http://dx.doi.org/10.1677/ERC-09-0089
 [XYI]  - YAO DACHUN ET AL, "High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 19 OCT 2007, (20071019), vol. 282, no. 42, ISSN 0021-9258, pages 31038 - 31045, XP002732473 [X] 1,5,14 * page 31039, column left * [Y] 10 [I] 3

DOI:   http://dx.doi.org/10.1074/jbc.M704703200
 [YP]  - ZIEGLER TILMAN ET AL, "Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis", JOURNAL OF CLINICAL INVESTIGATION, (20130801), vol. 123, no. 8, pages 3436 - 3445, XP002732474 [YP] 8 * page 3444, column right *

DOI:   http://dx.doi.org/10.1172/JCI66549
 [Y]  - BOGDANOVIC ELENA ET AL, "Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization.", JOURNAL OF CELL SCIENCE 1 SEP 2006, (20060901), vol. 119, no. Pt 17, ISSN 0021-9533, pages 3551 - 3560, XP002732505 [Y] 10 * page 3558, column right *

DOI:   http://dx.doi.org/10.1242/​jcs.03077
ExaminationEP2848631
    - CUNNINGHAM B C ET AL, "HIGH-RESOLUTION EPITOPE MAPPING OF HGH-RECEPTOR INTERACTIONS BY ALANINE-SCANNING MUTAGENESIS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, (19890602), vol. 244, no. 4908, doi:10.1126/SCIENCE.2471267, ISSN 0036-8075, pages 1081 - 1085, XP000025308

DOI:   http://dx.doi.org/10.1126/science.2471267
    - METHENY-BARLOW LINDA J ET AL, "The enigmatic role of angiopoietin-1 in tumor angiogenesis.", CELL RESEARCH OCT 2003, (200310), vol. 13, no. 5, ISSN 1001-0602, pages 309 - 317
by applicant   - SCHWABER, J; COHEN, E. P., "Human x Mouse Somatic Cell Hybrid Clones Secreting Immunoglobulins of Both Parental Types", NATURE, (1973), vol. 244, pages 444 - 447
    - ALMAGRO, J. C.; FRANSSON, J., "Humanization of antibodies", FRONTIERS IN BIOSCIENCE, (2008), vol. 13, pages 1619 - 1633
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.